Nuvalent, Inc.
生物技术研究
Cambridge，Massachusetts 5,617 位关注者
#PreciselyTargetedTherapies for patients with cancer
关于我们
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. To learn more, visit www.nuvalent.com.
- 网站
-
https://www.nuvalent.com/
Nuvalent, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Cambridge，Massachusetts
- 类型
- 私人持股
- 创立
- 2017
地点
-
主要
获取路线
One Broadway 14th Floor
US，Massachusetts，Cambridge，02142
Nuvalent, Inc.员工
动态
-
?? The #NuCrew is hiring! We are on the lookout for a Manager, Clinical Operations! ?? Learn more about this role and other new opportunities here: https://lnkd.in/eKbtRUPT #NuTalent #hiring #biotech
-
-
??? Nuvalent is supporting the GO2 for Lung Cancer 2024 Navigator Workshop & Centers of Excellence Summit this week! Learn more about GO2 for Lung Cancer: https://go2.org/ #biotech #lungcancer #oncology
-
-
We look forward to attending Lung Cancer Research Foundation Annual Evening of Innovation Gala in NYC. Together, let's raise awareness for #lungcancer research and patients on #WorldCancerResearchDay! Learn more about how you can support the #LCRF and get involved: https://lnkd.in/ehBbvuTm #biotech #oncology
-
-
Today at #ESMO2024, we presented new preclinical data characterizing the intracranial activity of our ROS1-selective inhibitor zidesamtinib in comparison to FDA-approved or investigational dual TRK/ROS1 inhibitors. Find our poster here: https://lnkd.in/eKEbdTJk
-
-
Catch our exciting updates today at the #ESMO2024 Congress in Barcelona! ? Presentation of updated Phase 1 data from the ongoing ARROS-1 Phase 1/2 clinical trial of zidesamtinib, a novel ROS1-selective inhibitor, with pivotal data expected in 2025 ? Presentation of updated Phase 1 data from the ongoing ALKOVE-1 Phase 1/2 clinical trial of NVL-655, a novel ALK-selective inhibitor, with pivotal data expected in 2025 ? Announcement of our ALKAZAR study, a Phase 3 trial of NVL-655 for TKI-na?ve patients with advanced ALK-positive NSCLC, with planned initiation in 1H 2025 Read more here: https://lnkd.in/esirygBm
-
We are pleased to announce our new manuscript in Cancer Discovery, a journal by the American Association for Cancer Research, describing the design and characterization of NVL-655 and detailing Nuvalent’s approach to rationally targeting ALK. Thank you to our preclinical and clinical collaborators! ? Find our paper here: https://lnkd.in/gfwFJwZU
-
-
Look for updates from our #ALK and #ROS1 #NSCLC programs at the #ESMO24 Congress this weekend, including updated Phase 1 data from our ALKOVE-1 and ARROS-1 clinical trials. Tune in to our conference call on 9/14 to learn more! ? Read the press release: https://lnkd.in/ek2S5vW9 ? #biotech #data #clinicaltrials
-
HOT JOB ALERT ?? Associate Director, Regulatory Affairs - CMC ?? Interested in joining the #NuCrew? Learn more about this role and other new opportunities here: https://lnkd.in/dPwrpJha #NuTalent #hiring #biotech
-
-
?? Join our CEO James Porter and CFO Alex Balcom, MBA, CPA at the Morgan Stanley Annual Healthcare Conference on Wednesday, September 5th, 2024, at 1:05 p.m. ET in New York City! Recordings of the webcasts will be available on our website for 30 days. https://lnkd.in/eCQ2mudJ $NUVL #biotech #oncology
-